Corvus Pharms

CRVS NASDAQ
3.380
-0.260
-7.14%
已收盘, 16:23 06/14 EDT
开盘
3.590
昨收
3.640
最高
3.633
最低
3.280
成交量
12.55万
成交均量(3M)
7.14万
52周最高
13.48
52周最低
3.220
换手率
0.43%
市值
9,863.98万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Corvus Pharms CRVS股票价格,Corvus Pharms股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
展开 >

最近浏览

名称
价格
涨跌幅